Scarica l'app Stockscreener
6.19
2.98%
-0.19
Pre-mercato:
6.19
Precedente Chiudi:
$6.38
Aprire:
$6.38
Volume 24 ore:
1.08M
Relative Volume:
0.58
Capitalizzazione di mercato:
$1.07B
Reddito:
$291.85M
Utile/perdita netta:
$554.00K
Rapporto P/E:
-814.47
EPS:
-0.0076
Flusso di cassa netto:
$27.93M
1 W Prestazione:
-0.80%
1M Prestazione:
+2.48%
6M Prestazione:
-9.37%
1 anno Prestazione:
+26.84%
Intervallo 1D:
$6.12
$6.435
Intervallo di 1 settimana:
$5.83
$6.435
Portata 52W:
$4.30
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Nome
Xeris Biopharma Holdings Inc
Settore
Telefono
844-445-5704
Indirizzo
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.19 | 1.10B | 291.85M | 554.00K | 27.93M | -0.0076 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2023-08-28 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Craig Hallum | Buy |
| 2021-11-17 | Iniziato | SVB Leerink | Outperform |
| 2021-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-02-18 | Iniziato | Piper Sandler | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Leerink Partners | Outperform |
| 2018-07-16 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
XERS Technical Analysis | Trend, Signals & Chart Patterns | XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) - ChartMill
What Xeris Biopharma Holdings (XERS)'s Profit Return and Higher 2026 Guidance Means For Shareholders - Sahm
Xeris Biopharma Holdings, Inc. (XERS) Stock Price, News, Quote & History - Yahoo Finance
Xeris Biopharma Quality Draws Market Attention Through Growth Signals - Kalkine Media
Xeris Biopharma Holdings, Inc. (XERS) Latest Stock News & Headlines - Yahoo Finance
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings - simplywall.st
Vanguard Group Inc. Buys 1,358,760 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
TradingKey - TradingKey
Xeris Biopharma (XERS) Stock Price, News & Analysis $XERS - MarketBeat
Xeris Biopharma Q3 EPS Forecast Decreased by HC Wainwright - MarketBeat
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Profit Turnaround And Guidance Hike - Sahm
Xeris forecasts $380M-$390M 2026 revenue as Recorlev commercial expansion ramps in H2 - MSN
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit - Yahoo Finance
Number of shareholders of Xeris Biopharma Holdings, Inc. – DUS:2B30 - TradingView
Xeris Biopharma Q1 Earnings Call Highlights - MarketBeat
Q1 2026 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Xeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 ProfitabilityWhat's Changed - Yahoo Finance
Xeris Biopharma Reports First Quarter 2026 Financial Results - BioSpace
Xeris (XERS) Q1 2026 Earnings Call Transcript - The Globe and Mail
Rekorlev-driven revenue lifts Xeris Biopharma (XERS) to Q1 2026 profitability - Stock Titan
Earnings call transcript: Xeris Biopharma Q1 2026 reports solid growth By Investing.com - Investing.com South Africa
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XERS: Q1 revenue jumped 43% year-over-year, prompting a raised full-year outlook to $380–$390 million - TradingView
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Achieves First Profit, Beats Q1 Estimates with 95% Recorlev Surge - ChartMill
Earnings Flash (XERS) Xeris Biopharma Holdings Posts Q1 EPS $0.01, vs. FactSet Est of $0.01 Loss per Share - marketscreener.com
Xeris Biopharma: Q1 Earnings Snapshot - Barchart.com
Xeris Biopharma (XERS) surges with 38% Q1 revenue growth and profit - Stock Titan
Xeris Pharmaceuticals Q1 2026 earnings preview - MSN
Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biop - GuruFocus
Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Xeris Biopharma’s chief legal officer sells $103,805 in stock By Investing.com - Investing.com Canada
Xeris Biopharma’s chief legal officer sells $103,805 in stock - Investing.com
Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan - Stock Titan
Xeris Biopharma (XERS) to Release Earnings on Thursday - MarketBeat
Xeris Biopharma Reports Third Quarter 2024 Financial Results - Quantisnow
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? - MSN
Xeris Biopharma expects full-year 2025 revenue above estimates - MSN
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026 - BioSpace
Xeris Biopharma Holdings, Inc. ($XERS) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
Xeris Biopharma (NASDAQ: XERS) details 2026 votes on pay, board, auditor - Stock Titan
Xeris (XERS) Year-Ahead Outlook | Q4 2025: EPS Exceeds ExpectationsDark Pool - Cổng thông tin điện tử Tỉnh Sơn La
Xeris Biopharma Holdings Inc Azioni (XERS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xeris Biopharma Holdings Inc Azioni (XERS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hecht Beth | See Remarks |
Apr 01 '26 |
Sale |
5.99 |
16,667 |
99,859 |
1,209,840 |
| Brady James Aloysius | Director |
Mar 30 '26 |
Sale |
5.54 |
10,834 |
60,036 |
89,166 |
1.92%
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):